Kyntra Bio to Participate in Upcoming Investor Conferences

Core Insights - Kyntra Bio, formerly known as FibroGen, is actively participating in investor conferences to engage with potential investors and stakeholders [1][2]. Group 1: Investor Conferences - Kyntra Bio will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, from 2:40-3:10 PM ET in a virtual format [1]. - The company will also present at the Leerink Global Healthcare Conference on March 11, 2026, from 2:20-2:50 PM ET in Miami, FL [1]. - Management will be available for one-on-one meetings during these conferences, and interested investors are encouraged to reach out for scheduling [1]. Group 2: Company Overview - Kyntra Bio is focused on developing novel therapies in oncology and rare diseases, with its lead product, Roxadustat (EVRENZO™), approved in multiple countries for treating anemia in chronic kidney disease patients [2]. - The company is evaluating a Phase 3 trial for Roxadustat in treating anemia associated with lower-risk myelodysplastic syndromes in the U.S. [2]. - Kyntra Bio is also developing FG-3246, a first-in-class antibody-drug conjugate targeting CD46, currently in Phase 2 for metastatic castration-resistant prostate cancer, along with FG-3180, a CD46-targeted PET biomarker [2].